SHORT-TERM RESULTS OF CURCUMIN, QUERCETIN, HYALURONIC ACID AND CHONDROITIN SULFATE (IALURIL SOFT GELS®) IN THE MANAGEMENT OF CHRONIC PROSTATITIS/PRIMARY PROSTATE PAIN SYNDROME: A SINGLE-CENTER PROSPECTIVE STUDY

Valerio Iacovelli^1*Matteo Vittori¹Marco Carilli¹Chiara Cipriani²Marta Signoretti¹Michele Antonucci¹Filomena Petta¹Beatrice Filippi³Giulia Di Giovanni³Francesco Maiorino¹Filippo Antonino Maria Saccà¹Giuseppe Stella¹Carlo Brocca¹Pierluigi Bove¹

• ¹Minimally Invasive and Robotic Urology Unit, Tor Vergata University Hospital, Rome, Italy, Rome, Italy
• ²Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
• ³Urology Unit, San Carlo di Nancy General Hospital - GVM Care and Research, Rome, Italy

Aim of the study: Management of Chronic Prostatitis/Primary Prostate Pain Syndrome (CP/PPPS) is challenging, with conflicting outcomes. This study evaluated the efficacy of a food supplement containing Curcumin, Quercetin, Hyaluronic Acid, and Chondroitin Sulfate (Ialuril Soft Gels®) in CP/PPPS treatment. Materials and methods: Data from consecutive male patients with CP/PPPS were prospectively collected between Oct-2022 and Jan-2023. Patients with maximum flow rate <15 ml/s, post-void residual >150 ml, or prior prostate surgery were excluded. Collected variables included age, BMI, prostate volume (PVol), and serum PSA. Patients completed standardized questionnaires assessing pain, lower urinary tract symptoms (LUTS), and erectile function: Symptom Severity Index (SSI), Symptom Frequency Questionnaire (SFQ), NIH Chronic Prostatitis Symptom Index (NIH-CPSI) (pain and LUTS domains), International Prostate Symptom Score (IPSS), IPSS Quality of Life (IPSS-QoL), and International Index of Erectile Function (IIEF-5). Changes in scores were evaluated at baseline, and at 30 and 90 days post-enrolment. Patients took 2 gelcaps of Ialuril Soft Gels® daily (curcumin 200 mg, quercetin 200 mg, hyaluronic acid 100 mg, chondroitin sulfate 200 mg) for 60 days. Results: Twenty patients were analyzed. Median baseline values were: age 50 years (IQR 46–51), BMI 24.2 (22.8–28.3), PVol 42 ml (30–52), PSA 1.0 ng/ml (0.8–1.8), SSI 54 (27–55), SFQ 20 (13–26), NIH-CPSI pain 10 (8–13), LUTS 7 (4–8), IPSS 13 (10–18), IPSS-QoL 3 (2–3), IIEF-5 17 (14–22). SSI and SFQ scores showed statistically significant improvement at both 30 days [SSI 45 (22–49), p < 0.001; SFQ 16 (11–20), p = 0.035] and 90 days [SSI 33 (17–42), p < 0.001; SFQ 13 (9–16), p < 0.001]. IPSS and NIH-CPSI domains improved significantly at 30 days [IPSS 12 (10–13), p = 0.002; pain 6 (5–9), p < 0.001; LUTS 7 (2–9), p = 0.033] but not at 90 days (p > 0.05). No significant changes were observed in IPSS-QoL and IIEF-5 scores. No adverse events were reported. Conclusions: Ialuril Soft Gels® appears effective in reducing pain and urinary symptoms in CP/PPPS patients over short-term follow-up.